Park Medi World Q3 FY26: Revenue Up 17.76% to ₹410 Crore, PAT Jumps 15.78% to ₹52.8 Crore
Park Medi World Limited reported Q3 FY26 consolidated revenue of ₹410 crore, up 17.76% YoY. PAT increased by 15.78% to ₹52.8 crore. For 9M FY26, revenue grew 17.25% to ₹1,218.9 crore, and PAT surged 42.60% to ₹196.8 crore. The company also announced strategic acquisitions of two hospitals.
The significant increase in revenue and profit, coupled with strategic acquisitions, indicates positive business development and operational efficiency, which is likely to have a substantial impact on the company's market position and investor confidence.
The company reported strong year-on-year growth in revenue and profit for both the quarter and nine-month period, along with strategic acquisitions that are expected to drive future growth.
Park Medi World Limited announced its Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025 (Q3 FY26).
For the third quarter of FY26, the company reported consolidated revenues of ₹410 crore, marking a significant increase of 17.76% compared to ₹348.1 crore in the same period last year. EBITDA for the quarter stood at ₹99.4 crore, a 20.05% rise from ₹82.8 crore in Q3 FY25, with the EBITDA margin improving to 24.25% from 23.79%. Profit After Tax (PAT) for the quarter was ₹52.8 crore, an increase of 15.78% from ₹45.6 crore in the prior year. The PAT margin was 12.89% compared to 13.11% in Q3 FY25. Basic Earnings Per Share (EPS) for the quarter was ₹1.35, up from ₹1.19 in Q3 FY25.
For the nine months ended December 31, 2025 (9M FY26), consolidated revenues grew by 17.25% to ₹1,218.9 crore from ₹1,039.7 crore in 9M FY25. EBITDA for the nine-month period increased by 12.17% to ₹317.0 crore from ₹282.6 crore, with an EBITDA margin of 26.00% (compared to 27.18% in 9M FY25). PAT for the nine months surged by 42.60% to ₹196.8 crore from ₹138.0 crore in 9M FY25. The PAT margin improved to 16.14% from 13.27% in 9M FY25. Basic EPS for the nine months was ₹5.09, up from ₹3.59 in 9M FY25.
The company also highlighted strategic acquisitions, including Febris Multi-Speciality Hospital in New Delhi and KP Institute of Medical Sciences in Agra. These acquisitions are expected to enhance the company's presence and optimize clinical resources. The management emphasized steady operational performance, healthy revenue growth supported by patient volumes and improved case mix, and continued execution of their growth strategy. They remain focused on disciplined capital allocation, balance sheet strength, and measured expansion, with priorities on seamless integration of acquired assets and improving asset utilization.
What to do with a filing like this
Park Medi World Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Park Medi World Limited. Read the original for the full detail.